|
Use
of chemotherapy plus a monoclonal antibody against HER2 for
metastatic breast cancer that overexpresses HER2.
Slamon
DJ, Leyland-Jones B, Shak S, et al. N Engl J Med. 2001;344:783-92.
Weekly
trastuzumab and paclitaxel therapy for metastatic breast cancer
with analysis of efficacy by her2 immunophenotype and gene
amplification.
Seidman
AD, Fornier MN, Esteva FJ, et al. J Clin Oncol. 2001;19:2587-95.
Phase
I study of stealth liposomal doxorubicin in combination with
gemcitabine in the treatment of patients with metastatic breast
cancer.
Rivera
E, Valero V, Syrewicz L, et al. J Clin Oncol. 2001;19:1716-22.
Cardiovascular
effects of raloxifene hydrochloride.
Saitta
A, Morabito N, Frisina N, et al. Cardiovasc
Drug Rev. 2001;19:57-74.
Greek
Brief Pain Inventory: Validation and utility in cancer pain.
Mystakidou
K, Mendoza T, Tsilika E, et al. Oncology. 60(1):35-42, 2001.
Antalgic
treatment of pain associated with bone metastases [Review].
Reale
C, Turkiewicz AM, Reale CA. Critical Reviews in Oncology-Hematology.
37(1):1-11, 2001 Jan.
Treatment
of metastatic breast cancer with somatostatin analogues--a
meta-analysis.
Dolan
JT, Miltenburg DM, Granchi TS, Miller CC 3rd, Brunicardi FC.
Ann Surg Oncol. 2001;8:227-33.
Local
hyperthermia, radiation, and chemotherapy in recurrent breast
cancer is feasible and effective except for inflammatory disease.
Feyerabend
T, Wiedemann GJ, Jager B, Vesely H, Mahlmann B, Richter E.
Int J Radiat Oncol Biol Phys. 2001;49:1317-25.
Liarozole
fumarate (R85246): in the treatment of ER negative, tamoxifen
refractory or chemotherapy resistant postmenopausal metastatic
breast cancer.
Goss
PE, Strasser K, Marques R, et al. Breast
Cancer Res Treat. 2001;64:177-88.
Doxorubicin
and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide
as first-line therapy for women with metastatic breast cancer:
final results of a randomized phase III multicenter trial.
Jassem
J, Pienkowski T, Pluzanska A, et al. J Clin Oncol. 2001;19:1707-15.
Dose-dense
sequential chemotherapy with epirubicin and paclitaxel versus
the combination, as first-line chemotherapy, in advanced breast
cancer: a randomized study conducted by the Hellenic Cooperative
Oncology Group.
Fountzilas
G, Papadimitriou C, Dafni U, et al. J Clin Oncol. 2001;19:2232-9.
Chemotherapy
for advanced breast cancer: what influences oncologists' decision-making?
Grunfeld
EA, Ramirez AJ, Maher EJ, et al. Br
J Cancer. 2001;84:1172-8.
Clinical
and pharmacologic study of the epirubicin and paclitaxel combination
in women with metastatic breast cancer.
Grasselli
G, Vigano L, Capri G, et al. J Clin Oncol. 2001;19:2222-31.
The
changeable nature of patients' fears regarding chemotherapy:
Implications for palliative care.
Passik
SD, Kirsh KL, Rosenfeld B, McDonald MV, Theobald DE. Journal
of Pain & Symptom Management. 21(2):113-120, 2001 Feb.
Dose-intensive
epirubicin-based chemotherapy is superior to an intensive
intravenous cyclophosphamide, methotrexate, and fluorouracil
regimen in metastatic breast cancer: A randomized multinational
study.
Ackland
SP, Anton A, Breitbach GP, et al. Journal of Clinical Oncology.
19(4):943-953, 2001 Feb 15.
Efficacy
of docetaxel 60 mg/m(2) in patients with metastatic breast
cancer according to the status of anthracycline resistance.
Ando
M, Watanabe T, Nagata K, Narabayashi M, Adachi I, Katsumata
N. Journal of Clinical Oncology. 19(2):336-342, 2001 Jan 15.
Reduced
cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated
doxorubicin and cyclophosphamide compared with conventional
doxorubicin and cyclophosphamide in a randomized, multicenter
trial of metastatic breast cancer.
Batist
G, Ramakrishnan G, Rao CS, et al. Journal of Clinical Oncology.
19(5):1444-1454, 2001 Mar 1.
Phase
I study of infusional paclitaxel in combination with the P-glycoprotein
antagonist PSC 833.
Chico
I, Kang MH, Bergan R, et al. Journal of Clinical Oncology.
19(3):832-842, 2001 Feb 1.
The
gemcitabine/epirubicin/paclitaxel trials in advanced breast
cancer.
Conte
P, Salvadori B, Donati S, et al. Oncology
(Huntington). 15(2 Suppl 3):41-43, 2001 Feb.
A
short course of induction chemotherapy followed by two cycles
of high-dose chemotherapy with stem cell rescue for chemotherapy
naive metastatic breast cancer.
Elias
AD, Richardson P, Avigan D, et al. Bone Marrow Transplantation.
27(3):269-278, 2001 Feb.
Thymidine
kinase and thymidylate synthase in advanced breast cancer:
Response to tamoxifen and chemotherapy.
Foekens
JA, Romain S, Look MP, Martin PM, Klijn JGM. Cancer Research.
61(4):1421-1425, 2001 Feb 15.
Single-agent
oxaliplatin in pretreated advanced breast cancer patients:
A phase II study.
Garufi
C, Nistico C, Brienza S, et al. Annals of Oncology. 12(2):179-182,
2001 Feb.
Docetaxel/gemcitabine:
Salvage chemotherapy in anthracycline-pretreated patients
with advanced breast cancer.
Georgoulias
VA. Oncology (Huntington). 15(2 Suppl 3):18-24, 2001 Feb.
Treatment
of advanced breast cancer with gemcitabine and vinorelbine.
Oncology (Huntington).
Hortobagyi
GN, Connally NB. 15(2 Suppl 3):15-17, 2001 Feb.
Phase
I study of vinorelbine and paclitaxel by 3-hour simultaneous
infusion with and without granulocyte colony-stimulating factor
support in metastatic breast carcinoma.
Ibrahim
NK, Buzdar AU, Valero V, Dhingra K, Willey J, Hortobagyi GN.
Cancer. 91(4):664-671, 2001 Feb 15.
Gemcitabine,
paclitaxel, and trastuzumab in metastatic breast cancer.
Miller
KD, Sisk J, Ansari R, et al. Oncology (Huntington). 15(2 Suppl
3):38-40, 2001 Feb.
Gemcitabine
and paclitaxel as salvage therapy in metastatic breast cancer.
Murad
AM, Guimaraes RC, Aragao BC, Scalabrinineto AO, Rodrigues
VH, Garcia R. Oncology (Huntington). 15(2 Suppl 3):25-27,
2001 Feb.
Phase
II study of docetaxel, doxorubicin, and cyclophosphamide as
first-line chemotherapy for metastatic breast cancer.
Nabholtz
JM, Mackey JR, Smylie M, et al. Journal
of Clinical Oncology. 19(2):314-321, 2001 Jan 15.
Gemcitabine
plus cisplatin in breast cancer.
Nagourney
RA. Oncology (Huntington). 15(2 Suppl 3):28-33, 2001 Feb.
Vinorelbine,
cisplatin and continuous infusion of 5-fluorouracil (ViFuP)
in metastatic breast cancer patients: A phase II study.
Nole
F, Munzone E, Mandala M, et al. Annals
of Oncology. 12(1):95-100, 2001 Jan.
Response
to chemotherapy is a major parameter-influencing long-term
survival of metastatic breast cancer patients.
Pierga
JY, Robain M, Jouve M, et al. Annals
of Oncology. 12(2):231-237, 2001 Feb.
Caelyx
(stealth liposomal doxorubicin) in the treatment of advanced
breast cancer [Review].
Ranson
MR, Cheeseman S, White S, Margison J. Critical Reviews in
Oncology-Hematology. 37(2):115-120, 2001 Feb.
Prognostic
factors and long-term survival in 585 patients with metastatic
breast cancer treated with epirubicin-based chemotherapy.
Ryberg
M, Nielsen D, Osterlind K, Skovsgaard T, Dombernowsky P. Annals
of Oncology. 12(1):81-87, 2001 Jan.
Biweekly
gemcitabine, doxorubicin, and paclitaxel as first-line treatment
in metastatic breast cancer.
Sanchez-Rovira
P, Jaen A, Gonzalez E, et al. Oncology (Huntington).
15(2
Suppl 3):44-47, 2001 Feb.
Docetaxel
monotherapy in heavily pretreated metastatic breast cancer:
a multicenter, community-based feasibility trial.
Schmidinger
M, Budinsky AC, Wenzel C, et al. Cancer Chemotherapy &
Pharmacology. 47(1):57-62, 2001 Jan.
Gemcitabine
as single-agent therapy in the management of advanced breast
cancer.
Seidman
AD. Oncology (Huntington). 15(2 Suppl 3):11-14, 2001 Feb.
Use
of chemotherapy plus a monoclonal antibody against HER2 for
metastatic breast cancer that overexpresses HER2.
Slamon
DJ, Leyland-Jones B, Shak S, et al. New England Journal of
Medicine. 344(11):783-792, 2001 Mar 15.
Docetaxel
in patients with anthracycline-resistant advanced breast cancer.
Vici
P, Belli F, Di Lauro L, et al. Oncology. 60(1):60-65,
2001.
Gemcitabine,
epirubicin, and paclitaxel combinations in advanced breast
cancer.
Conte
P, Salvadori B, Donati S, Landucci E, Gennari A. Semin Oncol.
2001;28:15-7.
Accelerated-intensified
cyclophosphamide, epirubicin, and fluorouracil (CEF) compared
with standard CEF in metastatic breast cancer patients: results
of a multicenter, randomized phase III study of the Italian
Gruppo Oncologico Nord-Ouest-Mammella Inter Gruppo Group.
Del
Mastro L, Venturini M, Lionetto R, et al. J Clin Oncol. 2001;19:2213-21.
A
phase II trial of mitomycin C, 5'-deoxy-5-fluorouridine, etoposide
and medroxyprogesterone acetate (McVD-MPA) as a salvage chemotherapy
to anthracycline-resistant tumor in relapsed breast cancer
and its mechanism(s) of antitumor action.
Kim
R, Osaki A, Tanabe K, Kojima J, Toge T. Oncol Rep. 2001;8:597-603.
Thymidine
kinase and thymidylate synthase in advanced breast cancer:
Response to tamoxifen and chemotherapy.
Foekens
JA, Romain S, Look MP, Martin PM, Klijn JGM. Cancer Research.
61(4):1421-1425, 2001 Feb 15.
Aromatase
inhibitors in the treatment and prevention of breast cancer
[Review].
Goss
PE, Strasser K. Journal of Clinical Oncology. 19(3):881-894,
2001 Feb 1.
Cost-effectiveness
analysis of exemestane compared with megestrol in patients
with advanced breast carcinoma.
Hillner
BE, Radice D. Cancer. 91(3):484-489, 2001 Feb 1.
Combined
tamoxifen and luteinizing hormone-releasing hormone (LHRH)
agonist versus LHRH agonist alone in premenopausal advanced
breast cancer: A meta-analysis of four randomized trials.
Klijn
JGM, Blamey RW, Boccardo F, Tominaga T, Duchateau L, Sylvester
R. Journal of Clinical Oncology. 19(2):343-353, 2001 Jan 15.
Immunotherapy:
On the edge between experimental and clinical oncology [Review].
Fagnoni
FF, Della Cuna GR. Journal of Chemotherapy. 13(1):15-23, 2001 Feb.
A
phase I, open label, dose ranging trial of intravenous bolus
zoledronic acid, a novel bisphosphonate, in cancer patients
with metastatic bone disease.
Berenson
JR, Vescio R, Henick K, et al. Cancer Cytopathology. 91(1):144-154,
2001 Jan 1.
A
clinical review [Review].
Crandall
C. Risedronate - Archives of Internal Medicine. 161(3):353-360,
2001 Feb 12.
Preclinical
development of metalloproteasis inhibitors in cancer therapy
[Review].
Giavazzi
R, Taraboletti G. Critical Reviews in Oncology-Hematology.
37(1):53-60, 2001 Jan.
Development
of matrix metalloproteinase inhibitors in cancer therapy [Review].
Hidalgo
M, Eckhardt SG. J Natl Cancer Inst. 93(3):178-193, 2001 Feb
7.
Clinical
significance of MT1-MMP mRNA expression in breast cancer.
Mimori
K, Ueo H, Shirasaka C, Mori M. Oncology Reports. 8(2):401-403,
2001 Mar-Apr.
Adjuvant
clodronate treatment does not reduce the frequency of skeletal
metastases in node-positive breast cancer patients: 5-year
results of a randomized controlled trial.
Saarto
T, Blomqvist C, Virkkunen P, Elomaa I. Journal of Clinical
Oncology. 19(1):10-17, 2001 Jan 1.
Matrix
metalloproteinase-2 (MMP-2) is associated with the risk for
a relapse in postmenopausal patients with node-positive breast
carcinoma treated with antiestrogen adjuvant therapy.
Talvensaari-Mattila
A, Paakko P, Blanco-Sequeiros G, Turpeenniemi-Hujanen T. Breast
Cancer Research & Treatment. 65(1):55-61, 2001 Jan.
Zoledronic
acid in cancer patients with bone metastases: Results of Phase
I and II trials.
Berenson
JR. Semin Oncol. 2001;28:25-34.
Zoledronic
acid reduces skeletal-related events in patients with osteolytic
metastases.
Berenson
JR, Rosen LS, Howell A, et al. Cancer. 2001;91:1191-200.
The
role of zoledronic acid in cancer: Clinical studies in the
treatment and prevention of bone metastases.
Coleman
RE, Seaman JJ. Semin Oncol. 2001;28:11-6.
Photodynamic
therapy for chest wall progression from breast carcinoma is
an underutilized treatment modality.
Allison
R, Mang T, Hewson G, Snider W, Dougherty D. Cancer Cytopathology.
91(1):1-8, 2001 Jan 1.
Palliative
radiotherapy of bone metastases: an evaluation of outcome
measures.
Barton
MB, Dawson R, Jacob S, Currow D, Stevens G, Morgan G. Journal
of Evaluation in Clinical Practice. 7(1):47-64, 2001 Feb.
Intrathecal
treatment of neoplastic meningitis due to breast cancer with
a slow-release formulation of cytarabine.
Jaeckle
KA, Phuphanich S, van den Bent MJ, et al. British Journal
of Cancer. 84(2):157-163, 2001 Jan 19.
Corticosteroids
in advanced cancer.
Wooldridge
JE, Anderson CM, Perry MC. Oncology (Huntington). 15(2):225-+,
2001 Feb.
Colonic
metastases from breast cancer.
Babb
RR, Trollope M. Surg Endosc. 2001;15:530.
Methodology
for treatment evaluation in patients with cancer metastatic
to bone.
Cook
RJ, Major P. J Natl Cancer Inst. 2001;93:534-8.
Osteoprotegerin
Diminishes Advanced Bone Cancer Pain.
Luger
NM, Honore P, Sabino MA, et al. Cancer
Res. 2001;61:4038-4047.
Metastatic
breast cancer: understanding current management options.
McGinn
K, Moore J. Oncol Nurs Forum. 2001;28:507-12; quiz 513-4.
High-dose
epirubicin plus docetaxel at standard dose with lenograstim
support as first-line therapy in advanced breast cancer.
Milla-Santos
A, Milla L, Rallo L, Solano V. Am J Clin Oncol. 2001;24:138-42.
|
